Here's another interesting link about ClO2 (Chlorine Dioxide) gas. This is a study about low-level ClO2 in the air, given to rats over a long period of time. The authors were attempting to determine whether it was safe for use in settings where killing bacteria, viruses, molds, etc. would be desirable, such as in a hospital.On July 30, 2010, and again on October 1, 2010, the United States Food and Drug Administration (FDA) warned against the use of the product "Miracle Mineral Supplement", or "MMS", which when made up according to instructions produces chlorine dioxide. MMS has been marketed as a treatment for a variety of conditions, including HIV, cancer, autism, and acne. The FDA warnings informed consumers that MMS can cause serious harm to health and stated that it has received numerous reports of nausea, diarrhea, severe vomiting, and life-threatening low blood pressure caused by dehydration.[37][38]Chlorine dioxide is toxic, hence limits on exposure to it are needed to ensure its safe use. The United States Environmental Protection Agency has set a maximum level of 0.8 mg/L for chlorine dioxide in drinking water.[35] The Occupational Safety and Health Administration (OSHA), an agency of the United States Department of Labor, has set an 8-hour permissible exposure limit of 0.1 ppm in air (0.3 mg/m3) for people working with chlorine dioxide.[36]
Friday, December 7, 2018
MMS and Chlorine Dioxide warnings
Wednesday, October 31, 2018
Herpes virus link to bipolar disorder and depression - Science & research news | Frontiers
For first time, study shows HHV-6 virus can infect neurons & possibly cause cognitive disturbances leading to psychiatric disorders: Frontiers in Microbiology
Saturday, October 27, 2018
Neurological Lyme disease: What you should know
Sunday, October 7, 2018
Genome-wide analysis of Borrelia turcica and 'Candidatus Borrelia tachyglossi' shows relapsing fever-like genomes...
Infect Genet Evol. 2018 Sep 18;66:72-81. doi: 10.1016/j.meegid.2018.09.013. [Epub ahead of print]
Tuesday, September 25, 2018
Mast Cell Activation May Underlie 'Chronic Fatigue Syndrome'
Mast Cell Activation May Underlie 'Chronic Fatigue Syndrome'
Miriam E. Tucker
March 13, 2018
Clinical Assessment and Laboratory Testing
- Skin: urticaria, angioedema, flushing
- Gastrointestinal: nausea, vomiting, diarrhea, abdominal cramping
- Cardiovascular: hypotensive syncope or near syncope, tachycardia
- Respiratory: wheezing
- Naso-ocular: conjunctival injection, pruritus, nasal stuffiness
Treatment May Ease Some ME/CFS Symptoms
Tuesday, September 18, 2018
Treating Lyme depression and fatigue
|
Sunday, August 26, 2018
Lyme disease: Obstacles to diagnosis and effective treatment
New breathalyzer can flag early onset Parkinson's
The Times of Israel
[Aug 26, 2018 is when I found this article. —Bob]
New breathalyzer can flag early onset Parkinson's, Israeli researchers say:
New breathalyzer can flag early onset Parkinson's, Israeli researchers say | The Times of Israel
Technion team also identifies breath signatures of 17 other ailments that could be detected by the handheld breath analysis device, including Alzheimer's and gastric cancer
home page
A team of researchers at Israel's Technion Institute of Technology has developed a device they say can detect the early onset of Parkinson's disease by analyzing the breath of users.
Since antiquity physicians have been evaluating their patients by the odor of their bodily fluids: the stools and urine of noblemen's children were often sniffed daily by their physicians. Of these, exhaled breath is the most accessible and useful source for monitoring health and disorders, the researchers said in a paper, one of several they published on the subject.
Armed with this knowledge, the researchers, led by Prof. Hossam Haick of the Department of Chemical Engineering and Russell Berrie Nanotechnology Institute of the Technion, set out on a quest to find out if a breathalyzer could help identify patients who are at the very early stages of Parkinson's disease.
Get The Start-Up Israel's Daily Start-Up by email and never miss our top stories Free Sign Up
Parkinson's disease is a degenerative condition that affects dopamine-producing neurons in an area of the brain. Dopamine, a chemical, is responsible for coordinating movement. Symptoms of the disease develop gradually over the years, causing patients to experience hand tremors, limb rigidity and gait and balance problems. And although there is no cure, the affliction is treated by dealing with the symptoms by using dopaminergic medications, according to the Parkinson's Foundation.
Because people with Parkinson's start experiencing symptoms only later in the course of the disease, when a substantial number of neurons have already been damaged, scientists are trying to find ways to identify bio-markers that can lead to an earlier diagnosis and hopefully more tailor-made treatments to help slow down its progression.
More than 10 million people worldwide live with Parkinson's, with some 60,000 Americans diagnosed each year and nearly 1 million forecast to have the disease in the United States by 2020. The direct and indirect costs of Parkinson's — which include treatment, social security payments and lost income — is estimated at nearly $25 billion per year in the US alone, the Parkinson's Foundation says on its website.
The breath analyzer developed by the Technion multidisciplinary team, which included electrical and chemical engineers and medical researchers, consists of miniaturized sensors that can help detect the early onset of the disease and help with follow-up treatment, Haick said in a phone interview with The Times of Israel.
The 10x5x5-centimeter (4x2x2-inch) handheld device holds a set of 40 chemical sensors that have been trained via algorithms to detect specific markers in the breath that could flag the onset of the disease.
The researchers collected breath samples of Parkinson's patients and loaded it onto the sensors, which have chemicals that react to molecules in the breath. These reactions are transformed into electrical signals, with the breath of Parkinson's patients marked by the algorithms with their own kind of electrical signal. The sensors in the breathalyzer were then trained to identify those specific breath compositions that indicate Parkinson's, said Haick. So when people are tested with the device, the sensors are able to distinguish the breath of those who have the disease from the breath of those who don't.
Over 80% accuracy
The researchers conducted their studies with the breathalyzer over a number of years on a sample population of up to 500 people, Haick said. In their most recent study, published in ACS Chemical Neuroscience last month, Haick and his team set out to find out if their device could detect differences in the breath of patients with early-stage, not-yet-treated Parkinson's disease.
The researchers tested the device on the exhaled breath of 29 newly diagnosed patients who had not yet begun taking medication for their illness. When comparing the sensor output to that of 19 control subjects of similar age, they found that the breathalyzer managed to detect early Parkinson's disease with over 80 percent accuracy, almost as good an outcome as an ultrasound scan of the brain.
"Just as a dog can be trained to memorize a smell," said Haick, "so we have trained our sensors in the breathalyzer to identify those that are specific to Parkinson's."
Although the device still needs to be improved and validated with larger studies, the researchers say that it has potential as a small, portable system to screen at-risk individuals without the need for big and expensive analytical tools or highly trained specialists.
To commercialize the device, the baton now must be picked up by either pharma companies or startups, Haick said. The Technion has already reached licensing agreements for the technology with seven entities, some of them big international firms and some startups, in the US, Israel, Asia, Germany and Toronto, he said.
"I think it could be a point of care device," Haick said, where doctors can screen patients in their clinics. "The development of the disease can be slowed down, if detected and treated at an early stage."
The researchers have also identified the breath characteristics of 17 diseases. "We have proven that each of these diseases has a signature in breath," he said, so they could use the same technology for those diseases, including multiple sclerosis, Alzheimer's, lung cancer and gastric cancer, he said.
Wednesday, August 22, 2018
A New Tick Species Found in USA
We don't yet know how the long-horned tick came to the United States, how it's spreading, or what it's capable of doing. All we know is that it's here.
Tuesday, August 21, 2018
Three Lyme Disease Apps
Sunday, August 19, 2018
Thursday, August 16, 2018
Bay Area Lyme Fndn (@BayAreaLyme) | Twitter
Bob Cowart
Email: bob@cowart.com
Monday, August 13, 2018
Story on Lyme from Mother Jones
Monday, August 6, 2018
New FDA approved Nanotrap Lyme antigen test
Press Release: Ceres Nanosciences, Inc., Manassas, Virginia
July 12, 2018
http://www.ceresnano.com/press-release-breakthrough http://www.ceresnano.com/press-release-breakthrough
Ceres Nanosciences (Ceres) announced today that is has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its new point-of-care Nanotrap® Lyme Antigen Test System.
Under the Breakthrough Device program, formerly the Expedited Access Pathways program, the FDA works with a test developer to reduce the time and cost from development to approval.
The Ceres' Nanotrap® Lyme Antigen Test System is a powerful diagnostic test that is intended to be available in point-of-care settings, like a physician's office or a walk-in clinic. Requiring only a patient's urine sample, it will deliver results to the physician and patient at the earliest stages of infection, when treatment is most successful.
"We're truly grateful to receive the FDA's Breakthrough Device designation for the Nanotrap® Lyme Antigen Test System," said Ross Dunlap, Chief Executive Officer of Ceres Nanosciences. "This will accelerate our delivery to patients of a much needed test for Lyme disease, a devastating and increasingly common infectious disease that can cause irreparable harm if not detected and treated early on."
To achieve Breakthrough Device designation, a device must demonstrate compelling potential to provide more effective diagnosis for life-threatening or irreversibly debilitating diseases. In addition, the device must meet at least one of the following criteria: represent breakthrough technologies; no approved or cleared alternatives exist; offer clinically meaningful advantages over existing approved or cleared alternatives; or the availability of which is in the best interest of patients.
About Ceres Nanosciences, Inc.
Ceres Nanosciences is a privately held company, located in Prince William County, Virginia, focused on the development of research and diagnostic products using its unique and proprietary Nanotrap® particle technology. The Nanotrap® particle technology provides powerful biomarker capture and biofluid sample processing capabilities for a wide array of diagnostic applications and sample handling needs. The Nanotrap® particle technology was invented at George Mason University and developed under funding from the National Institutes of Health (NIH). With support from the NIH, the Defense Advanced Research Projects Agency (DARPA), the Bill and Melinda Gates Foundation, and the Commonwealth of Virginia, Ceres is focused on incorporating this technology into a range of innovative diagnostic products. Learn more at www.ceresnano.com http://www.ceresnano.com
Press Contact:
Ross M. Dunlap
Ceres Nanosciences, Inc
1.800.615.0418 ext. 202
rdunlap@ceresnano.com mailto:rdunlap@ceresnano.com
Tuesday, July 31, 2018
Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease
Monday, July 30, 2018
Willy Burgdorfer’s statement about tick attachment time
—Willy Burgdorfer
How long does a tick have to be on you...
Wednesday, July 11, 2018
Found a tick on you and want it tested for disease? TestMyTick
Tulsa Dermatologist Creates Test My Tick Kit
TestMyTick.com
About Us
We've partnered with the preeminent Laboratory of Medical Zoology (LMZ), to offer a battery of tests to detect disease-causing microbes in ticks. Your tick can be tested for over 20 different disease causing organisms that ticks can carry (like Lyme disease, Rocky Mountain Spotted Fever, and newly discovered diseases like Powassan, Heartland, and Colorado Tick Fever Virus). We now share that data as part of Tick-Borne Disease Network passive surveillance that we hope will provide unprecedented insights to who is being bitten by ticks, when they get bitten, and what pathogens those ticks are carrying. We encourage everyone to SAVE THE TICKS! ....for Testing!
LMZ-
Laboratory of Medical Zoology (LMZ)
Fernald Hall, University of Massachusetts
Amherst, MA 01003
http://www.tickdiseases.org/
Unusually High Levels of HHV Found in the Brains of Those With Alzheimer's
Tuesday, July 10, 2018
WSJ Article- New Effort for Lyme Disease Vaccine Draws Early Fire
New Effort for Lyme Disease Vaccine Draws Early Fire
By
Sumathi Reddy
Updated July 9, 2018 3:48 p.m. ET
Efforts to bring a vaccine for Lyme disease to the market have run aground amid heated debate over the years.
Now, a European company is in the early stages of creating a vaccine for the increasingly common tick-borne disease. Lyme disease patient-advocacy groups—who disagree with the protocols used by most doctors for the diagnosis andtreatment of Lyme disease—are already raising concerns.
Saturday, July 7, 2018
Study of NLY01 at Hopkins: Stops Parkinson's disease progression
July 7, 2018
Experimental Drug Halts Parkinson's Progression, Study Says; Johns Hopkins University researchers
An experimental drug developed by Johns Hopkins University researchers appears to slow down the progression of Parkinson's disease and its symptoms in mice,
The researchers said that the drug called NLY01 has been proven in studies to block the degradation of brain cells that is the leading cause of Parkinson's disease. The treatment has been used in the past to treat diabetes, researchers said in the university statement.
The study's results, which were published last month in the journal Nature Medicine, reported that NLY01 works by binding to glucagon-like peptide-1 receptors on the surface of certain cells. Similar drugs are used widely in the treatment of type 2 diabetes to increase insulin levels in the blood, the university statement said.
"NLY01 also prolongs the life and reduces the behavioral deficits and neuropathological abnormalities in the human A53T α-synuclein (hA53T) transgenic mouse model of α-synucleinopathy-induced neurodegeneration,"
Parkinson's disease is a progressive disorder of the nervous system that affects about 1 million people in the United States and 10 million worldwide,
"It is amazingly protective of target nerve cells," Ted Dawson, director of the Institute for Cell Engineering at the Johns Hopkins University School of Medicine, said in the university's statement.
The drug is expected to move to clinical trials later this year, the statement said. Dawson added that if planned clinical trials are successful in humans, it could be one of the first treatments to directly target the progression of Parkinson's disease, not just the muscle rigidity, spasmodic movements, fatigue, dizziness, dementia, and other symptoms of the disorder.
Dawson cautioned that NLY01 must still be tested for safety as well as effectiveness in people but based on the safety profile of other similar drugs, he does not anticipate any major hurdles on the way to human trials.
The researcher added that they are hopeful that NLY01 could, in a relatively short period of time, make an impact on the lives of those with Parkinson's, the university statement said.
Friday, July 6, 2018
Eco researchers discuss Lyme
Tuesday, July 3, 2018
Press release about a vaccine against Lyme disease
Valneva is now finalizing the detailed Phase 2 protocol and, subject to requisite regulatory approvals, expects to enter Phase 2 clinical development by the end of 2018.
Monday, June 18, 2018
An excellent page of collected Lyme articles
Thursday, May 31, 2018
Blood banks still accepting blood from Lyme patients
. . . a Lyme Disease patient in Arkansas is raising awareness about the fact that she, and other Lyme Disease patients, can still give blood.
According to the CDC, Lyme disease is one of the fastest-growing infectious diseases in the United States. The CDC also reports that Lyme disease can live in blood that is stored for donation.
Even still, patients in Arkansas say they can still donate blood, despite the risk of passing it to others.Tuesday, May 29, 2018
Saturday, May 19, 2018
More Lyme workingroup updates
| |||||||||||||||||||||||||||||||||||||